Early detection, anytime, anywhere.
Personalized cancer screening combining at-home testing, AI-powered risk analysis and continuous monitoring.
A European digital oncology platform at TRL 5, advancing toward clinical trials and IVDR certification — built for institutional partners and health system integration.
From screening to life-saving outcomes
€4.8M
Revenue from EU diagnostic operations
EU EUA
Among first EU-authorized COVID-19 test providers
18+
Years combined diagnostic expertise
TRL 5
Cancer platform laboratory validated
Commercial track record established through COVID-19 diagnostics (2020–2022). Expertise now applied to at-home cancer screening.
The Survival Gap
Cancer does not always wait for symptoms.
It often develops silently until it is too late.
Across Europe, many cancers are still diagnosed at advanced stages, when survival rates drop significantly. Early detection changes this trajectory by enabling faster intervention, more effective treatment, and better outcomes. We believe early cancer detection must be affordable, accessible, and continuous for everyone.
Detecting the disease at its earliest stage can increase survival to over 90%, before outcomes decline sharply as it progresses diagnosed at advanced stages.
Source: European Cancer Information System (ECIS), 2023.
"Early detection of cancer greatly improves the chances for successful treatment."
— World Health Organization (WHO)
>90% survival when detected early
Early detection dramatically improves clinical outcomes
Detecting cancer at its earliest stage can increase survival to over 90%, before outcomes decline sharply as the disease progresses.
>90%
EARLY
Source: European Cancer Information System (ECIS), 2023.
60%
MID
<15%
LATE
What We Do
At-Home Cancer Screening
Simple finger-prick biomarker testing designed for early detection outside traditional clinical settings.
AI Risk Analysis
Transforming biological signals into structured, actionable risk insights.
Digital Health Platform
Connecting testing, interpretation, dashboards, and monitoring in one continuous system.
Continuous Monitoring
Supporting regular screening over time instead of one-time diagnostics.
Next-Generation Decentralized AI Oncology Diagnostics
Unibioscience is defining a new category by transitioning oncology from episodic, hospital-based testing to continuous, at-home, AI-guided monitoring.
Platform Overview
This is more than a test. Unibioscience combines at-home screening, digital interpretation, AI-based risk analysis, and continuous monitoring in one integrated platform.
0.14
Risk Index
LOW RISK
Active Screening
Next test: Oct 12, 2026
Longitudinal Tracking
JAN
MAR
MAY
JUL
SEP
Test management
Result interpretation
Health dashboard
Longitudinal tracking
How It Works
Create your health profile
Receive your personalized test kit
Perform the test at home
Scan with the mobile app
Track results over time
Receive guidance and next steps
Share key health data to personalize your screening.
We ship a clinical-grade kit tailored to your risk profile.
Collect your sample easily from the comfort of home.
Activate your kit and sync data securely in seconds.
View trends and risk scores in your personal dashboard.
Get clear clinical recommendations and follow-up actions.
Rethinking Cancer Diagnostics
We don't replace the clinic. We extend its reach.
Results Without the Wait
No lab referrals. No appointment backlogs. Screening initiated at home, results tracked digitally within the same session.
Complete Privacy
No clinic visits. No sample mailing. Testing conducted entirely in the home environment with end-to-end data encryption.
Geography-Independent Access
Removing barriers for patients in rural areas, underserved regions, and populations without specialist access.
Continuous, Not One-Time
Recurring subscription screening replaces episodic diagnostics with longitudinal risk intelligence over time.
Aligned with Europe’s Beating Cancer Plan
The platform supports earlier detection, prevention, and equitable access, designed to integrate seamlessly with European health systems and oncology pathways.
Access
Prevention
Early Detection
Health Equity
Driving clinical inclusivity by removing geographic and logistical barriers to high-quality cancer screening.
Empowering individuals and clinicians with longitudinal risk insights to support proactive prevention strategies.
Transitioning oncology from reactive diagnostics to persistent, AI-guided surveillance for high-risk populations.
Standardizing the quality of oncological monitoring across regions and care settings, independent of local resource constraints.
At‑Home Cancer Test Platform
Integrated Diagnostics Dashboard
Future Screening Panels (under development)
Clinical-grade cancer screening tailored to your biological profile, integrated with our AI risk engine for longitudinal health security.
Continuous Monitoring
Women's Panel
- CA15-3 / MUC-1 — Breast cancer marker
CA27-29 — Breast cancer progression tracking
CA125 / HE4 — Ovarian cancer risk mapping
CEA — Cross-cancer early signal detection
AI risk scoring with 6-month recurring monitoring
Continuous Monitoring
Men's Panel
- PSA — Prostate-specific antigen tracking
CEA — Colorectal early signal detection
AFP — Liver cancer marker
AI-driven trend analysis and risk stratification
Annual clinical review pathway
Continuous Monitoring
General Panel
- Tg — Thyroid cancer marker
CA19-9 / CEA — Pancreatic and colon signals
AFP — Liver function and oncological risk
Comprehensive inflammatory marker screening
Unlimited risk re-stratification
All biomarker panels are based on validated lateral flow immunoassay (LFIA) technology. Results are interpreted through our proprietary AI risk engine and reviewed by qualified clinical professionals. Panels are under development — not yet available for commercial use.
21M annual cancer cases
>90% survival when detected early
94% sensitivity
Validation & Clinical Readiness
Validated
Prototype
298
Validation Datasets
Based on 298 pilot laboratory validation datasets. Clinical-scale validation targeting TRL 6 is in preparation.
94%
Sensitivity
TRL 5
Progression
IVDR
Roadmap
Laboratory validation completed and transitioning toward clinical development.
Our Ecosystem Partners
Partnership discussions ongoing. Contact us to explore collaboration.
CLINICAL VALIDATION PARTNER
LABORATORY PARTNER
ACADEMIC INSTITUTION
DIGITAL HEALTH COLLABORATOR
Clinical Partner
REGULATORY PARTNERSHIP
Clinical Trial Expertise. Built In.
ABINGDON HEALTH LTD LOGO
Europe's leading lateral flow immunoassay development and IVD clinical trial organization.
🔬 LFIA Development & Optimization
📋 IVDR & CE-Mark Clinical Trial Design
✅ ISO 13485 Certified Infrastructure
Unibioscience has engaged Abingdon Health Ltd as its designated clinical trial and regulatory compliance partner. Abingdon Health brings accredited laboratory infrastructure, deep IVDR pathway experience, and proven expertise in lateral flow immunoassay validation at clinical scale.
This partnership ensures every stage of our development roadmap — from clinical study design to regulatory submission — is executed to the standards required by European health authorities.
Ready to Partner with the Future of Cancer Care?
Join leading institutions in scaling precision oncology. Authorize access to sensitive clinical data and strategic roadmaps.
Pitch Deck
Company overview, mission, and growth strategy.
Technical Files
Deep dive into CTDNA dynamics and AI architecture.
Validation Reports
Clinical study summaries and 94% sensitivity data.
Financial Model
Subscription revenue projections and market scaling.
Secure Data Room | Strict Confidentiality Protocols
Our Ecosystem Partners
Partnership discussions ongoing. Contact us to explore collaboration.
Clinical Validation Partner
Laboratory Partner
Academic Institution
Digital Health Collaborator
Clinical Evidence & Validation
Our platform combines the detection of methylated ctDNA dynamics with global clinical interoperability. By establishing high-fidelity longitudinal baselines, we ensure that early oncological signals are validated against diverse datasets, providing a standardized pathway from TRL 5 technology to large-scale healthcare implementation. Progression to TRL 6 is targeted through upcoming clinical studies.
Sensitivity Validation
298 validation datasets achieving 94% sensitivity across multi-modal cohorts.
Global IVDR Roadmap
Systematic transition to large-scale clinical implementation and IVDR compliance.
Clinical evidence and peer-reviewed studies supporting our precision oncology platform.
AI-Driven Risk Scoring
0.82
0.41
98%
Baseline Risk Index
AI Detection Confidence
Algorithm Accuracy
The AI & Risk Engine
Deep Learning for Precision Oncology
Our AI combines biomarker signals, personal health profile, and relevant contextual factors to generate structured risk insights and support earlier action.
Dynamic Risk Scoring
Adaptive scoring that evolves with new clinical data.
Genomic Integration
Real-time predictive modeling of oncological risk based on genomic and clinical data.
Deep integration with European genomic databases.
Standardized interpretation
Risk stratification
Actionable next-step guidance
Scientific Advisory Board
Prof. Jean-Pierre Gillet
Clinical validation and oncology translation expertise
Professor Gillet leads our clinical validation strategy, bridging the gap between innovative biomarker research and practical oncology applications. His extensive background in translational medicine ensures our screening protocols meet the highest standards of diagnostic accuracy and clinical relevance for healthcare systems worldwide.
Leadership
Orhan Avur – CEO
18+ years in enzymes, diagnostics and life sciences. Strong background in commercial strategy, global markets and scaling businesses, with experience across Europe, the Middle East and Asia.
Dr. Noreddine Aggoun Baeyens – CTO
Expert in biomedical engineering and diagnostic technologies, with experience in assay development, data integration and platform architecture. Focused on translating scientific innovation into scalable healthcare solutions.
Validation Partners & Ecosystem
Secure Access Gateway
Join leading institutions in scaling precision oncology. Request authorization to access sensitive materials and roadmaps.
Scientific Access
Request access to validation and technical materials
Investor Access
Request access to investor materials and data room
Premium Access Request
Authorize access to clinical data rooms and strategic oncology roadmaps for qualified reviewers.